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Objectives: Radioimmunotherapy (RIT) has emerged as a potential treatment option for 
multiple myeloma (MM). In humans, a dosimetry study recently showed the relevance 
of RIT using an antibody targeting the CD138 antigen. The therapeutic efficacy of RIT 
using an anti-CD138 antibody coupled to 213Bi, an α-emitter, was also demonstrated in 
a preclinical MM model. Since then, RIT with β-emitters has shown efficacy in treating 
hematologic cancer. In this paper, we investigate the therapeutic efficacy of RIT in the 
5T33 murine MM model using a new anti-CD138 monoclonal antibody labeled either 
with 213Bi for α-RIT or 177Lu for β-RIT.
Methods: A new monoclonal anti-CD138 antibody, 9E7.4, was generated by immu-
nizing a rat with a murine CD138-derived peptide. Antibody specificity was validated by 
flow cytometry, biodistribution, and α-RIT studies. Then, a β-RIT dose-escalation assay 
with the 177Lu-radiolabeled 9E7.4 mAb was performed in KalwRij C57/BL6 mice 10 days 
after i.v. engraftment with 5T33 MM cells. Animal survival and toxicological parameters 
were assessed to define the optimal activity.
results: α-RIT performed with 3.7  MBq of 213Bi-labeled 9E7.4 anti-CD138 mAb 
increased median survival to 80 days compared to 37 days for the untreated control and 
effected cure in 45% of animals. β-RIT performed with 18.5 MBq of 177Lu-labeled 9E7.4 
mAb was well tolerated and significantly increased mouse survival (54 vs. 37 days in the 
control group); however, no mice were cured with this treatment.
conclusion: This study revealed the advantages of α-RIT in the treatment of MM in a 
preclinical model where β-RIT shows almost no efficacy.
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inTrODUcTiOn
Multiple myeloma (MM) represents 1% of all cases of cancer and 
10% of hematological malignancies (1). The physiopathology of 
MM consists of an uncontrolled proliferation of a monoclonal 
plasma cell in the bone marrow, resulting in the abnormal secre-
tion of a monoclonal immunoglobulin, known as paraprotein, 
which can be detected in patients’ serum or urine. Common 
features of MM include organ damage due to plasma cell prolif-
eration – also known as CRAB (hypercalcemia, renal failure, ane-
mia, and bone diseases) – at least one focal lesion, and a ratio of 
involved:uninvolved circulating light chain higher than 100 (2, 3). 
Depending on the patient’s age, standard clinical care comprises 
high-dose therapy, which may be combined with autologous stem 
cell transplantation (4). Although new drugs such as bortezomib 
and lenalidomide, and new indications, such as for thalidomide, 
have significantly improved the overall survival rate for patients, 
MM remains an incurable disease. Therefore, treatments must be 
constantly improved and new drugs or new strategies continu-
ously assessed.
In the past two decades, radioimmunotherapy (RIT) has 
emerged as a novel strategy in the anti-cancer arsenal. This 
therapeutic approach consists in specifically targeting tumor cells 
using an antibody coupled with a radionuclide. The radionuclide 
can then kill tumor cells by direct cytotoxicity as well as through 
a bystander effect (5–9). Among the radionuclides which have 
been tested in clinical trials, there are a few β– emitters, such as 131I, 
90Y, 177Lu, and a number of α-emitters such as 213Bi, 211At, or 225Ra 
(10–15). The efficacy of RIT depends on the choice of radionuclide, 
which is determined by the vector and the nature of the cancer 
(16). Indeed, the characteristics of α- and β-ionizing radiation 
differ, with α-particles having a much higher linear energy trans-
fer than β− emitters. Their range of penetration into tissues also 
differs: 50–100 μm for α-particles vs. 2–10 mm for β− particles. 
Based on these characteristics, α-particles appear better suited to 
treating disseminated cancer or micrometastases. The proof of 
concept of α-RIT in humans was provided by a clinical trial using 
an anti-CD33 mAb coupled to 213Bi as a treatment for myeloid 
leukemia (17). In this study, which was conducted in patients 
with large tumor burdens, no significant extramedullary toxicity 
was observed, nor was any complete response elicited supporting 
the hypothesis that α-RIT is more appropriate for treating small 
tumor volumes, residual disease, and micrometastases. Several 
clinical trials using β-RIT have also shown promising results with 
hematologic diseases, such as non-Hodgkin’s lymphomas (NHL) 
(18, 19) and with solid tumors, such as metastatic prostate cancer 
(20, 21). 177Lu appears to be an excellent candidate for RIT because 
of its short range of action (2 mm in tissues). This range is similar 
to that of 131I (2.9  mm), but shorter than that of 90Y (11  mm). 
This characteristic may reduce non-specific radiation damage 
to surrounding healthy tissues. In addition, its low ɣ-emission 
(208 keV) is an advantage in terms of radioprotection.
Our group has recently proven RIT to be effective in treating 
MM in humans (22) and α-RIT to be effective in an immunocom-
petent preclinical MM model (23). Both studies were performed 
with antibodies targeting the CD138 antigen, which is expressed 
by more than 95% of MM cells (24). CD138, or syndecan-1, is a 
member of the syndecan family of heparan sulfate proteoglycans; 
it is expressed by epithelial cells, precursor B cells, and normal 
plasma cells. It is also expressed at high levels in MM tumors 
(24–26) and is a key regulator in the disease (27). Finally, high 
levels of CD138 in patient serum are associated with poor prog-
nosis in MM disease progression (28–30).
Based on our study in MM patients with 131I-CD138 mAb (22), 
and the promising results obtained in treatment of NHL patients 
with β-RIT using an anti-CD20 mAb labeled with 90Y and 177Lu 
(18, 19), we decided to investigate the therapeutic efficacy of 
β-RIT in a preclinical model of MM using an anti-CD138 mAb 
coupled to 177Lu. We first generated and validated a new murine 
anti-CD138 antibody (9E7.4 mAb) and confirmed that it could 
effectively treat MM tumors using α-RIT. Then, we studied the 
tissue distribution of 177Lu-9E7.4 mAb and went on to perform 
dose-escalation and toxicity studies. Finally, we administered 
177Lu-9E7.4 at different times during disease progression.
MaTerials anD MeThODs
reagents, cell lines, and Mice
The bifunctional chelators S-2-(4-Isothiocyanatobenzyl)-1,4,7, 
10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA) 
and 2-(4-isothiocyanato-benzyl)-cyclohexyl-diethyletriamine-
penta-acetic (SCN-CHX-A″-DTPA) were purchased from 
Macrocyclics (USA). 177LuCl3 was purchased from Perkin Elmer 
(France) in 0.05 N HCl and 225Ac/213Bi generator was obtained 
from the Institute for Transuranium Elements (Karlsruhe, 
Germany). All buffers were prepared in H2O milliQ (0.2  μm; 
3 ppb; 18 MΩ) and Trace SELECT chemicals, when available. Rat 
IgG2a,κ anti-mouse CD138 antibody (clone 281-2) (ref.553712) 
was purchased from BD Pharmingen (France).
The 5T33 murine MM cell line was kindly provided by Dr. 
Harvey Turner (Department of Nuclear Medicine, Fremantle 
Hospital, Western Australia) with permission from Dr. J. Radl 
(TNO Institute, Leiden, The Netherlands) (31, 32). The SP2/
o-Ag14 myeloma cell line (ATCC® CRL-1581™) and the CTLL-2 
T lymphocyte cell line (ATCC® TIB-214™) were purchased from 
ATCC. All cell lines were cultured in RPMI 1640 medium (Life 
Technologies, France) containing 2 mM l-glutamine, 100 U/mL 
penicillin/100  μg/mL streptomycin and 10% heat-inactivated 
fetal calf serum (Life Technologies, France). Cells were incubated 
at 37°C, 5% CO2 in a humidity-saturated incubator.
Female C57BL/KalwRij mice were purchased from Harlan 
CPB and housed under conventional conditions at the UTE 
animal facility (SFR François Bonamy, IRS-UN, University of 
Nantes, license number: B-44-278). Experiments were approved 
by the local veterinary committee (License No. CEEA.2013.2). 
Mice were 8–12 weeks old at the time of experiments.
anti-cD138 9e7.4 mab Production and 
characterization
The 9E7.4 mAb was produced by immunization of a rat with a 
40-amino-acid peptide (GeneCust, Luxembourg) derived from 
the murine CD138 protein (aa 90–130) (GenBank: CAA80254.1). 
The isotype of 9E7.4 immunoglobulin was determined using a 
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Rat Isotyping Kit (RMT1, AbD serotec, UK) according to the 
manufacturer’s instructions.
The specificity and affinity of 9E7.4 mAb for CD138 were 
determined by flow cytometry (FACS Calibur™, BD Biosciences). 
Staining was detected indirectly with a secondary antibody, anti-
rat IgG/PE (Jackson-ImmunoResearch Laboratories).
anti-cD138 mab conjugation
A reaction solution containing a 20M excess of p-SCN-Bn-DOTA 
or SCN-CHX-A″-DTPA over the 9E7.4 mAb in 0.3M carbonate 
buffer pH 8.7 was incubated overnight (16 h) at room temperature 
(RT). Free chelator was eliminated and the conjugation buffer 
was exchanged for 0.25M NH4OAc, pH 7 (DOTA-9E7.4 mAb) 
or for PBS (CHX-A″-DTPA-9E7.4 mAb) by several centrifugal 
filtration steps using a 30-kDa cutoff Centricon concentrator 
(Amicon, Millipore). Integrity of the immunoconjugate was 
verified by size-exclusion HPLC. The conjugated 9E7.4 mAb was 
filtered through a 0.2-μm filter before storage at 4°C. The number 
of chelators per antibody was estimated at between 1 and 4 for 
p-SCN-Bn-DOTA and 2 for SCN-CHX-A″-DTPA by an 111In 
dilution assay (23) and/or mass spectrometry.
anti-cD138 mab radiolabeling
177Lu-chloride (370  MBq) was added to a solution containing 
DOTA-9E7.4 mAb, prepared in 0.25M NH4OAc pH 7 and 0.05M 
ascorbic acid buffer pH 5.5, and was adjusted to pH 5.5 with 0.5M 
NH4OAc. The reaction mixture was incubated at 42 ±  1°C for 
3  h. Complexation was then stopped by adding a 10M excess 
of EDTA and mixing for 15 min at RT. Labeling of anti-CD138 
9E7.4 mAb with 213Bi was performed as described in Chérel et al. 
(23). Radioiodination of anti-CD138 antibodies was performed 
as described in Fraker and Speck (33). All radiolabeled immu-
noconjugates were purified by gel filtration on a Sephadex G-25 
PD-10 desalting column (GE Healthcare Life Science, France) 
and eluted in 0.9% NaCl. The radiochemical purity was verified 
by instant thin layer chromatography (ITLC-SG) as described 
in Koppe et  al. (34), using citrate buffer (0.1M pH 4.5) as the 
mobile phase. For all experiments, purities of the 177Lu and 213Bi 
immunoconjugates were >98%, and purity of the 125I immu-
noconjugate was >95%. The immunoreactive fraction of the 
radiolabeled conjugates was determined using CD138-peptide-
coated magnetic beads. In all cases, the immunoreactive fraction 
was estimated at ≥80%.
Biodistribution
To determine the biodistribution of anti-mouse CD138 mAb, 
3 μg of 125I immunoconjugate were administered intravenously 
(i.v.) to tumor-free C57BL/KalwRij (n = 3 in each group). Mice 
were sacrificed 5 min, 4, and 24 h later. To study the tissue distri-
bution of 177Lu-9E7.4 mAb, 3 μg were i.v. injected into tumor-free 
C57BL/KalwRij (n  =  3 in each group). Mice were sacrificed 
5 min, 2, 8, 24, 48, 96, or 168 h later. For all experiments, tissues 
were collected and radioactivity was counted using a ɣ-counter 
(Wizard 1480, PerkinElmer, France). To account for physical 
decay of radioactivity, a triplicate standard dose was counted 
alongside the samples, and results were expressed as a percentage 
of injected dose per gram of tissue.
Dose-escalation and Therapeutic studies
Mice were engrafted with 1 × 106 5T33 MM cells. α-RIT was then 
performed on day 10 and β-RIT on day 10, 15, or 20. Animal 
survival was monitored over time. Mice were sacrificed when 
paralysis was detected and/or their weight dropped by 20%. In 
some cases, tumor masses were detected. For α-RIT, a single 
dose of 3.7 MBq 213Bi-9E7.4 mAb (n = 20) was injected i.v., in 
line with the previously described protocol (23). For β-RIT, a 
dose-escalation study was performed with i.v. injection of 3.7 
(n = 14), 7.4 (n = 5), 11.1 (n = 5), 14.8 (n = 5), 18.5 (n = 15), 
27.75 (n = 11), or 37 MBq (n = 7) 177Lu-9E7.4 mAb at a specific 
activity of 1480 ± 74 MBq/mg of antibody.
Toxicity study
To assess hematologic toxicity, blood was collected from the 
 retro-orbital sinus for leukocyte, erythrocyte, and thrombocyte 
counting on an automated hematology analyzer (Melet-
Schloesing Laboratories, France). Plasma was isolated from 
blood samples, pooled, and then used to monitor bone marrow, 
liver, and kidney toxicity based on the following biomarkers: 
Flt3-L – measured at different time points using DuoSet ELISA 
kits (DY427, R&D System, France), according to the supplier’s 
instructions – ASAT, ALAT, urea, and creatinin – concentrations 
of these markers were monitored using a Roche Cobas Analyzer 
(Roche, Meylan, France) with the appropriate reagents (Roche, 
Meylan, France).
statistical analyses
Data are presented as mean ± SEM. Statistical significance was 
determined using the Mann–Whitney test. Animal survival data 
were analyzed using Kaplan–Meier survival curves combined 
with the log-rank test. All statistical analyses were performed 
using GraphPad Prism® software (GraphPad Software).
resUlTs
characterization and Validation of the 
9e7.4 antibody
The 9E7.4 mAb was produced by immunizing a rat with a 40-aa 
peptide derived from the extracellular domain of murine CD138. 
The isotype of this antibody was determined to be IgG2a,κ, and its 
binding specificity was initially validated by ELISA using the 40-aa 
peptide (data not shown). This specificity was confirmed by flow 
cytometry on different cell lines and compared to that of 281-2 
mAb, a commercial anti-mouse CD138 mAb, which we had previ-
ously used (23) (Figure 1). The two anti-CD138 mAbs could bind 
to CD138-expressing MM cell lines 5T33 and SP2/o, whereas no 
binding to the negative control cell line was observed in either case. 
An in vitro competition assay indicated that these two anti-CD138 
mAbs bind to different epitopes on CD138 (data not shown). The 
binding affinity for mAbs 281-2 and 9E7.4 on 5T33 MM cells 
was comparable: 1 ×  10−10 and 2.3 ×  10−10M, respectively (data 
not shown). However, maximal binding of the 281-2 mAb was at 
least twofold more intense than 9E7.4 mAb binding (Figure 1). 
This difference in maximal binding led us to investigate the 
in vivo behavior of the 9E7.4 anti-CD138 mAb based on its tissue 
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FigUre 2 | Biodistribution of the two anti-mouse cD138 mabs. To 
complete 9E7.4 mAb characterization, biodistribution studies were performed 
in tumor-free C57BL/KalwRij mice by i.v. injection of 125I-radiolabeled 
(a) 9E7.4 mAb or (B) 281-2 mAb. Tissues were collected at 5 min, 4, and 
24 h after injection. Results are presented as the percentage of the injected 
dose normalized for tissue weight (% ID/g tissue). Values are given as 
mean ± SD (n = 3 mice per time point).
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distribution. The two mAbs were 125I-radioiodinated before injec-
tion into tumor-free C57BL/KalwRij mice, animals were sacrificed 
at 5 min, 4, and 24 h and the percentage injected dose per gram 
of tissue (% ID/g tissue) was calculated (Figure 2). These results 
showed the 9E7.4 mAb and the 281-2 mAb to distribute differ-
ently in blood, liver, and spleen. Five minutes after administration, 
25 ± 1.3% ID/g tissue for 9E7.4 mAb was detected in the blood 
compared to 7.4 ± 0.8% ID/g tissue for 281-2 mAb. 125I-281-2 mAb 
was taken up at a higher level in the liver compared to the 125I-9E7.4 
mAb, which could explain this difference. Liver uptake might be in 
part related to CD138 expression by mouse hepatocytes as the liver 
is a hematopoietic organ in mouse (35, 36). Differences were also 
noted for spleen uptake, with 9E7.4 mAb uptake increasing over 
time, whereas 281-2 mAb uptake remained stable. This difference 
may be related to the lower liver uptake, and the higher level of 
circulating 9E7.4 mAb molecules. Consequently, more molecules 
could reach the spleen and bind to the CD138+ plasma cells present 
in this secondary lymphoid organ (37). Beyond blood, liver, and 
spleen, the overall tissue distribution was quite comparable for the 
two mAbs, with a low uptake in other healthy organs.
To further endorse the specificity and relevance of the 9E7.4 
mAb, α-RIT using 213Bi was performed and the results compared 
with those from our previous study using the 281-2 mAb (23). 
Applying the same protocol as described in Chérel et  al. (23), 
1 × 106 5T33 MM cells were engrafted in mice, and α-RIT was 
performed by injecting 3.7 MBq of 213Bi-radiolabeled 9E7.4 mAb 
10 days later. Survival results are presented in Figure 3 and show 
that α-RIT significantly increased median survival (80  days) 
compared to the control group (37  days). Moreover, no mice 
survived in the control group, whereas 45% of the mice treated 
by α-RIT were still alive 110 days after tumor engraftment. All 
these data validated the use of 9E7.4 mAb in therapy.
Biodistribution of 177lu-9e7.4 mab
The tissue distribution of 9E7.4 mAb labeled with 177Lu was also 
studied in tumor-free C57Bl/KalwRij. Results are presented at 
different time points after injection in Figure 4. Five minutes after 
FigUre 1 | Flow cytometry characterization of 9e7.4 mab specificity. Staining with 9E7.4 mAb (black histogram), 281-2 mAb (gray histogram), or a rat 
IgG2a,κ isotype control (white histogram) revealed by a PE-conjugated anti-rat IgG secondary antibody performed on (a) CD138+ 5T33 cell line, (B) CD138+ SP2/o 
cell line, and (c) CD138− CTLL2 cell line. Flow cytometry was performed on a BD FACS Calibur™ Flow Cytometry System.
injection, 27.9 ±  1.4% ID/g tissue of antibody was detected in 
blood. As with 125I-9E7.4 mAb, a relatively high liver uptake was 
observed (45.9 ± 6.9% ID/g tissue). This level of uptake was due to 
specific binding, as confirmed by comparison with a 177Lu-isotype 
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FigUre 3 | survival curves after α-riT with 213Bi-9e7.4 mab. At day 0, 
all mice were engrafted with 1 × 106 of 5T33 cells by i.v. injection. α-RIT was 
performed on day 10 by i.v. administration of 3.7 MBq 213Bi-9E7.4 mAb 
(dotted line; n = 20). The control group (solid line; n = 44) received NaCl. 
p values were determined using the log-rank test and found to be highly 
significant, ****p < 0.0001 (3.7 MBq vs. control).
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FigUre 4 | Biodistribution of 177lu-9e7.4 mab. The 9E7.4 mAb radiolabeled with 177Lu was injected i.v. into tumor-free C57BL/KalwRij mice (n = 3). Tissues 
were collected 5 min, 2, 8, 24, 48, 96, and 168 h after injection. Results are presented as the percentage of the injected dose normalized for tissue weight  
(% ID/g tissue).
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control (data not shown). Uptake of 177Lu-9E7.4 mAb was also 
high in the spleen (27.6 ± 8.2% ID/g tissue between 2 and 48 h) 
and in the intestines (18.8 ±  9.1% ID/g tissue at 24 and 48  h) 
(Figure 4). Finally, accumulation of the 177Lu-9E7.4 mAb in other 
healthy organs was similar to what has been described with other 
radioimmunoconjugates (38).
Dose-escalation study with 177lu-9e7.4 
mab
Next, we tested the efficacy of β-RIT using the 177Lu-radiolabeled 
9E7.4 mAb in the 5T33 MM mouse model. As above, mice were 
engrafted with 1 × 106 5T33 MM cells 10 days before injecting seven 
different activities of 177Lu-9E7.4 mAb ranging from 3.7 to 37 MBq 
(Figure 5A). No statistical difference in median survival compared 
to the control group (37 days) was observed in any group receiving 
an activity below 18.5 MBq, indicating that below 18.5 MBq, β-
RIT had no therapeutic efficacy (Figure 5B). By contrast, survival 
was significantly increased compared to the control group in mice 
injected with 18.5  MBq, reaching 54  days. Nevertheless, even 
with this level of activity, no long-term survival was observed. 
Interestingly, the group which received 27.75  MBq exhibited a 
median survival of 48 days, which, although slightly higher than the 
control group (37 days), is lower than that obtained with 18.5 MBq. 
Once again, none of the mice survived. This effect was even more 
dramatic in the 37 MBq group, where median survival was reduced 
to 22 days – considerably less than the control group. In this group, 
no sign of paralysis was detected, but all mice had to be sacrificed 
due to excessive weight loss (Figure S1 in Supplementary Material) 
suggestive of toxicity rather than MM disease.
Together, these results indicate that 18.5 MBq of 177Lu-9E7.4 
mAb provides optimal activity in this murine MM model, 
increasing median survival. However, this activity is not sufficient 
to cure MM.
Toxicity study
To determine whether the limited efficacy of β-RIT was due to 
toxicity, we first assessed hematologic toxicity. To do this, leuko-
cyte, erythrocyte, and thrombocyte counts were monitored in the 
blood at different time points after initiating treatment (Figure 6). 
Results were normalized against the initial cell counts – before 
engraftment – and are expressed as percentages. Eleven days after 
β-RIT with 3.7 MBq, the leukocyte count was reduced by 24.5%; 
levels returned to normal at day 32 after initiation of the treatment 
(Figure 6A). With the 18.5 and 27.75 MBq activities, a dramatic 
nadir was reached with a decrease in leukocyte count of 75.5 
and 81.1%, respectively (Figure 6A). A return to normal levels 
was only achieved with the 18.5 MBq activity 40 days after treat-
ment, while in the 27.75 MBq group, leukocyte counts remained 
extremely low until the end of the study. Figure 6B shows that no 
major variations in erythrocyte counts were noted at any activity. 
By contrast, thrombocytes were also reduced by 26.3% for the 
18.5 MBq group and 48.1% for the 27.75 MBq group (Figure 6C). 
These reductions occurred later than the drop in leukocyte counts 
at day 22 after β-RIT. Together, these results indicate that of the 
cell populations examined (1), leukocytes appear to be the most 
sensitive to 177Lu; (2) thrombocytes are also sensitive but to a 
lesser extent; (3) β-ionizing radiation from 177Lu does not directly 
affect erythrocytes. The hematologic toxicity observed at 18.5 and 
day 0 day 10 
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27.75 MBq appears significant but reversible, or almost reversible, 
and might not be a major contributing factor to the mortality 
observed in these groups of animals.
We next studied non-hematologic toxicity in the bone marrow 
by monitoring the Flt3-L concentration in plasma (39) at different 
time points after β-RIT (Figure 6D). In control mice, the Flt3-L 
concentration was around 250  pg/mL at all time points, and a 
similar level was recorded for mice treated with 3.7 MBq. At day 
8 after β-RIT, the Flt3-L concentration increased to 500 pg/mL 
in mice injected with 18.5 and 27.75 MBq of 177Lu-9E7.4 mAb. 
Levels returned to normal in both groups on around day 32 and 
29, respectively, suggesting that myeloid toxicity was mild and 
reversible. Mice receiving a dose of 37 MBq exhibited a dramatic 
increase in Flt3-L level, reaching a mean of 1250 pg/mL, indica-
tive of major myeloid toxicity that might account for the rapid 
mortality observed in that group.
We also assessed liver toxicity by monitoring level of ASAT 
and ALAT concentrations in plasma and kidney toxicity by meas-
uring uremia and creatinemia. All markers were measured in the 
plasma at different time points after β-RIT (Figure 7). Figure 7A 
shows that, as in the control group, mice treated with 3.7, 18.5, 
and 27.75 MBq showed no variation in ASAT concentrations. In 
the 37 MBq group, a dramatic rise (≈700 UI/L) was noted 11 days 
after initiating the treatment. Similar results were observed for 
ALAT concentration (≈250 UI/L) and uremia (a 2.5-fold increase) 
(Figures 7B,C). Even though we noticed a certain variability in 
creatinemia over time in all the groups (Figure 7D), we observed 
a striking 2.5-fold increase in the 37 MBq group. Altogether, these 
results demonstrate that 37  MBq of 177Lu-9E7.4 mAb induces 
major liver and kidney toxicities.
β-riT with More advanced Myeloma 
Disease
At the optimal activity of 177Lu-9E7.4 mAb, no cure and no major 
toxicity were observed in our study. We, therefore, hypothesized 
that β-RIT might be more efficient in the treatment of more 
advanced MM disease. Indeed, due to its physical properties, 
it has been shown that 177Lu is better adapted to the treatment 
of small solid tumors and metastases (11). We, thus, decided 
to test β-RIT at day 15 or 20 after tumor engraftment. Survival 
rates are shown in Figure 8. These data confirmed that survival 
was improved for mice treated at day 10 (44 days) compared to 
the control group (31 days). However, median survival for mice 
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treated at day 15 or 20 after tumor engraftment did not improve 
further – 38 and 40.5 days, respectively. In addition, once again, 
no cure was recorded whatever the day of treatment, and none 
of the mice survived long term in any group. In summary, these 
results demonstrate that β-RIT is not an efficient treatment even 
for more advanced MM disease.
DiscUssiOn
The literature describes promising results with RIT as a treatment 
for disseminated cancer or micrometastases. Most of the studies 
have been done in hematologic cancer and micrometastases [for 
review, see Ref. (11)]. MM is a malignant hemopathy mainly 
located in the bone marrow, and RIT has already been shown to 
be effective in treating human MM through targeting of CD138 
(22). Our group has also demonstrated that α-RIT using the 
281-2 anti-CD138 mAb is efficient in the treatment of MM in an 
immunocompetent mouse model (23). All these results suggested 
that β-RIT, targeting CD138 antigen on tumor cells, could also be 
a promising approach in this disease.
In this study, we developed a new anti-mouse CD138 
mAb, 9E7.4, directed against a CD138-specific 40-aa peptide. 
Generation of proprietary hybridomas is an essential part of 
producing bispecific antibodies to reap the full benefit of these 
promising theranostic tools in nuclear medicine (40). The affinity 
of the 9E7.4 mAb for the CD138 antigen was similar to that of the 
281-2 mAb, in the range of 10−10M. However, maximal binding of 
9E7.4 mAb on CD138-expressing cells was at least twofold lower 
than maximal binding of 281-2 mAb (Figure 1). This difference 
might be due to the fact that they do not recognize the same epitope 
(data not shown), and how the two antibodies were generated. 
The 9E7.4 mAb was obtained using CD138-peptide immuniza-
tion, while 281-2 was generated using CD138-expressing cells. 
Thus, the glycosylation status of the CD138 in the immunization 
could have been different, and this could influence binding of 
these antibodies (supported by our unpublished data).
With this new 9E7.4 anti-mouse CD138 mAb, we confirmed 
our previous results demonstrating that in the 5T33 immuno-
competent MM mouse model, a single dose of α-RIT significantly 
raises median survival (80 vs. 37 days for control, untreated mice) 
and results in long-term survival for 45% of animals. In contrast, 
we showed that single-dose β-RIT performed in the same condi-
tions was not sufficient to cure mice developing MM.
This lack of efficacy cannot be ascribed to the new anti-
CD138 mAb since α-RIT was effective and tissue distributions of 
125I-radioiodinated 281-2 and 9E7.4 mAbs were very similar. The 
only differences observed were a lower uptake in the liver and a 
higher uptake in the spleen with both 125I and 177Lu-radiolabeled 
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9E7.4 mAb compared to 281-2 mAb. These differences might 
be explained as mentioned above and will have to be further 
investigated. However, the difference in liver uptake could be 
correlated to the lower binding level of 9E7.4 mAb to CD138 
compared to 281-2 mAb. Whatever the explanation, our results 
with 177Lu-9E7.4 mAb suggest that the therapeutic effect of β-
RIT is not enough to offset its toxicity. Thus, accumulation of 
177Lu-9E7.4 mAb appears to be deleterious in the bone marrow 
and liver. Many other studies performed with β-emitters have 
reported dose-limiting toxicity due to hematologic and bone 
marrow toxicities (19, 20, 41, 42). Here, we observed severe 
toxicity at 37  MBq at the hematologic, myeloid, hepatic, and 
kidney levels. Indeed, this activity was lethal and all the mice 
in this group had to be euthanized soon after RIT due to weight 
loss without any sign of disease progression (data not shown). 
A dramatic increase in Flt3-L in plasma confirmed that this 
treatment induced severe myeloid toxicity, as well as liver and 
kidney toxicity – as evidenced by ALAT, ASAT, urea, and cre-
atinin plasma concentrations. At 27.75 MBq, overall toxicity was 
less pronounced, but hematologic toxicity remained significant 
with a dramatic but almost reversible nadir for leukocytes. In 
the group of mice treated with 18.5 MBq of 177Lu-9E7.4 mAb, the 
leukocyte count returned to normal more rapidly. Leukocytes are 
more sensitive than thrombocytes and erythrocytes because the 
main target of ionizing radiation is DNA, not present in either of 
the latter. Moreover, the absence of nucleus and their short life 
span (7–10 days), suggests that the drop in thrombocyte levels 
is probably due to destruction of their precursors in the bone 
marrow. This hypothesis is supported by the increase in plasma 
Flt3-L noted for these two groups. Based on the uremia, there 
was no apparent kidney toxicity in these two groups, although 
creatinemia indicated a certain level of toxicity at 27.75  MBq. 
However, this experiment was only performed once and will 
have to be confirmed. Finally, at these activity levels, no hepatic 
toxicity was observed, even though it is important to note that in 
the 27.75 MBq group, one mouse had to be sacrificed soon after 
treatment as it exhibited the same signs of toxicity as animals in 
the 37 MBq group. All these results combine to indicate that the 
potential efficacy of the treatment at 27.75 MBq is counterbal-
anced by its toxicity. This suggests that 18.5 MBq is not only the 
maximum tolerated dose, but also that this is the only activity, 
administered as a single dose, allowing a certain efficacy of the 
treatment. However, in the group which received 18.5  MBq, 
despite the lower toxicity and statistical improvement in median 
survival compared to the control group, no cure was effected. 
Mice in this group were euthanized because of paralysis and an 
increase in plasma paraprotein, with one exception (data not 
shown). Therefore, even if the treatment was associated with 
some toxicity, animals mainly died due to tumor burden.
177Lu emits β-ionizing radiation in a range of 2  mm within 
tissues, and the literature indicates that these β-particles are more 
efficient in hematologic cancers with a high-tumor burden (41). In 
our hands, 10 days after 5T33 MM engraftment, tumor develop-
ment was weak, as previously shown using Luciferase-transfected 
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5T33 (23). Therefore, we thought that tumor burden at day 15 
or 20 after tumor engraftment might be more appropriate for 
β-RIT treatment. However, even when β-RIT was performed on 
a more developed disease, no improvement in median survival 
was noted, and no cures were effected.
The difference between α-RIT and β-RIT in our MM model 
could be due to a difference in the radiosensitivity of 5T33 MM 
cells. Our group has already demonstrated that 213Bi-281-2 mAb 
killed the human MM cell line U266 more efficiently than 131I-
281-2 mAb (26). Therefore, we will need to compare the sensitiv-
ity of 5T33 MM cells to α (213Bi) vs. β (177Lu) ionizing radiation at 
the cellular level.
Finally, although our study does not demonstrate any advan-
tage of using β-RIT to treat MM, some therapeutic efficacy was 
observed with 131I-B-B4 mAb in a previous dosimetric study (22). 
In the previous study, two of the four patients treated exhibited 
either a stabilization of the paraprotein level for 1 year, or a break 
in its progression. In addition, the patient for whom paraprotein 
levels stabilized also reported an analgesic effect, with a decrease 
in disease-related bone pain, which made it possible for them to 
return to work. In these circumstances, we believe that β-RIT 
could improve therapeutic efficacy in this preclinical MM model, 
perhaps by using a fractionated dose strategy. Indeed, with a 
fractionation approach, the total activity administered can be 
higher than that delivered with a single dose, allowing improved 
efficacy compared to a single-dose regimen while reducing 
toxicity (43). Dose fractionation has already shown its efficacy, 
notably in treatment of NHL (44–46) and also for metastatic 
prostate cancer (47). Finally, Orozco et  al. (48) demonstrated 
that β-RIT was less efficient when performed with 177Lu than 
with 90Y in an acute myeloid leukemia syngeneic mouse model. 
These authors hypothesized that the lower dose-rate and longer 
half-life of 177Lu could be responsible for the effect observed and 
suggested that dose fractionation is better adapted to the physi-
cal properties of this radionuclide. Therefore, further studies 
with the 177Lu-9E7.4 mAb in the immunocompetent MM mouse 
model will focus on assessing fractionated β-RIT treatment. In 
conclusion, this preclinical study indicates that, with a single 
dose, α-RIT is more efficient than β-RIT in treating MM in this 
mouse model.
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